Vallon says its abuse-deterrent ADHD drug candidate didn’t work in a clinical trial
Shares of Vallon Pharmaceuticals Inc. fell 77.5% in premarket trading on Monday after the company said its experimental formulation of an abuse-deterrent attention deficit hyperactivity...